Evelo Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Evelo Biosciences

16/03/2023 13:32

* Evelo Biosciences Inc  EVLO.OQ  reported a quarterly
adjusted
loss of 21 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Evelo Biosciences Inc's reported EPS for the quarter was a
loss
of 21 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Evelo Biosciences Inc shares had fallen by 80.4% this
quarter.
    * The company reported a quarterly loss of $23.54 million.
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $2.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 16 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.28          -0.21          Beat
 Sep. 30 2022      -0.33          -0.28          Beat
 Jun. 30 2022      -0.43          -0.40          Beat
 Mar. 31 2022      -0.58          -0.56          Beat